CALM-AF-AI study registered to evaluate dual AAV-Follistatin and VEGF gene therapy for age-related muscle loss
LONGEFI Signal
How this development was scored.
How authoritative and verifiable the underlying source is.
How prominent or noteworthy the development is based on its editorial classification.
How close this type of development sits to meaningful human clinical impact.
How strongly the development connects to companies and commercial or strategic context.
Measures significance, not direction or investment attractiveness.Methodology
A high LONGEFI Signal means the development is significant — not that it is positive news, a good investment, or expected to increase a company's share price.
Significance only. Direction-neutral: negative developments can score just as high. Not an investment rating, not a forecast, not a recommendation.
Event tier D · Tier ceiling 49 · LONGIFI_SIGNAL_V1
Quick take
A newly registered clinical trial, CALM-AF-AI, will investigate a combination genetic approach pairing AAV-Follistatin with an angiogenesis-inducing VEGF plasmid to address age-related muscle loss.
What happened
A study record has been registered on ClinicalTrials.gov under the title 'CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy'.
The clinical trial is designed to evaluate a dual-vector genetic approach, utilizing adeno-associated virus (AAV) vectors to deliver Follistatin alongside a plasmid encoding vascular endothelial growth factor (VEGF) to promote angiogenesis.
Why it matters
Follistatin acts as an antagonist to myostatin and other TGF-beta family ligands, promoting muscle hypertrophy, while VEGF acts as a primary stimulant for angiogenesis to improve local microvascular perfusion.
Sarcopenia has historically lacked approved therapeutic interventions; combining promyogenic gene expression with structural vascular support represents an emerging dual-mechanism paradigm in regenerative medicine.
Market impact
While many clinical candidates for age-related muscle preservation rely on oral small molecules, peptide mimetics, or monoclonal antibodies, this trial introduces a more complex genetic modality into clinical development.
The development confirms an appetite for advanced therapeutics targeting skeletal muscle vitality, which could establish a regulatory and clinical benchmark for other genetic interventions targeting frailty.
Sources
- U.S. National Library of MedicineCLINICALTRIALS:LONGEVITY